Achilles Therapeutics PLC Alpha and Beta Analysis
| ACHLDelisted Stock | USD 1.48 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Achilles Therapeutics PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Achilles Therapeutics over a specified time horizon. Remember, high Achilles Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Achilles Therapeutics' market risk premium analysis include:
Beta (0.44) | Alpha 0.68 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Achilles |
Achilles Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Achilles Therapeutics market risk premium is the additional return an investor will receive from holding Achilles Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Achilles Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Achilles Therapeutics' performance over market.| α | 0.68 | β | -0.44 |
Achilles Therapeutics Fundamentals Vs Peers
Comparing Achilles Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Achilles Therapeutics' direct or indirect competition across all of the common fundamentals between Achilles Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Achilles Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Achilles Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Achilles Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Achilles Therapeutics to competition |
| Fundamentals | Achilles Therapeutics | Peer Average |
| Return On Equity | -0.52 | -0.31 |
| Return On Asset | -0.3 | -0.14 |
| Current Valuation | (19.21 M) | 16.62 B |
| Shares Outstanding | 41.1 M | 571.82 M |
| Shares Owned By Insiders | 6.28 % | 10.09 % |
| Shares Owned By Institutions | 83.09 % | 39.21 % |
| Number Of Shares Shorted | 797.85 K | 4.71 M |
Achilles Therapeutics Opportunities
Achilles Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca | 12/24/2024 |
2 | 12 Health Care Stocks Moving In Tuesdays Pre-Market Session - Benzinga | 02/04/2025 |
3 | Achilles Therapeutics stock hits 52-week high at 1.41 - Investing.com | 03/13/2025 |
About Achilles Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Achilles or other delisted stocks. Alpha measures the amount that position in Achilles Therapeutics PLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Achilles Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Achilles Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Achilles Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Achilles Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Achilles Therapeutics. Please utilize our Beneish M Score to check the likelihood of Achilles Therapeutics' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Achilles Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Achilles Stock
If you are still planning to invest in Achilles Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achilles Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |